Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Redx Pharma has secured a $1m grant fromCARB-X, one of the world’s largest public-private partnerships, launched in July 2016 to speed up global antibacterial innovation and research.
Subscribe to our email newsletter
The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of the company’s research proposals, as evaluated by the CARB-X Advisory Board and the CARB-X team.
Today’s announcement by CARB-X showcases the first projects selected for the Powered by CARB-X portfolio, spotlighting Redx as a highly-respected partner of choice on a global stage.
Redx will receive US$1 million over 18 months, with an option for future tiered milestone payments, to drive scientific progress against globally challenging drug resistant Gram-negative bacteria.
This collaboration with CARB-X enables Redx to move its Gram-negative program into the next stage of development with a prospective partner.
Dr Neil Murray, Chief Executive Officer of Redx Pharma, said: “We are delighted to be collaborating with CARB-X, a truly innovative initiative that is targeting the development of new life-saving antibacterials and diagnostics. Receiving this grant today is testament to the great science that exists at Redx.
“This grant cements a path forward for our recently announced strategy, to secure external partners to ensure that our high quality anti-infective science will continue whilst we sharpen our focus on the clinical development of our oncology and immunology programs.”